Trends in transmitted drug resistance-associated mutations (TDRM) in HIV-1infection vary depending on geographic and cohort characteristics. The impact of TDRM among patients receiving fully active combination antiretroviral therapy (cART) is poorly characterized. This was a retrospective study of 801 HIV-1-infected treatment-naive patients from 2001 to 2009 who had pre-cART genotype resistance test results available. The prevalence of TDRM was compared for each year strata. Multivariate Cox proportional hazards regression models were used to assess factors associated with virologic failure at 48 weeks. TDRM was detected in 136 (17%) patients with ≥2 class TDRM in 20 patients. K103N/S was the most frequent (n=77). There were no changes in the prevalence of mutations over time (Ptrend=0.67). Six hundred and eleven patients were started on cART. Virologic failure occurred in 38% of those with TDRM and 24% of those without (p<0.01). In multivariate analysis, nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance was associated with a 1.5-fold increased risk of virologic failure. TDRM remains common among treatment-naive HIV-1-infected patients, affecting one in six patients. Transmission of NNRTI drug resistance was associated with risk of virologic failure despite initiation of genotype-guided cART.
Get full access to this article
View all access options for this article.
References
1.
PalellaFJ, BakerRK, MoormanAC, ChmielJS, WoodKC, BrooksJTet al.Mortality in the highly active antiretroviral therapy era: Changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr, 2006; 43,1:27–34.
2.
HolmbergSD, HamburgerME, MoormanAC, WoodKC, PalellaFJ. Factors associated with maintenance of long-term plasma human immunodeficiency virus RNA suppression. Clin Infect Dis, 2003; 37,5:702–707.
3.
RobbinsGK, JohnsonKL, ChangY, JacksonKE, SaxPE, MeigsJBet al.Predicting virologic failure in an HIV clinic. Clin Infect Dis, 2010; 50,5:779–786.
4.
JohnsonJA, LiJ, WeiX, LipscombJ, IrlbeckD, CraigCet al.Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-naïve populations and associate with reduced treatment efficacy. PLoS Med, 2008; 5,7:e158.
5.
MetznerKJ, GiulieriSG, KnoepfelSA, RauchP, BurgisserP, YerlySet al.Minority quasispecies of drug-resistant HIV-1 that lead to early therapy failure in treatment-naive and -adherent patients. Clin Infect Dis, 2009; 48,2:239–247.
6.
PillayD, BhaskaranK, JurriaansS, PrinsM, MasquelierB, DabisFet al.The impact of transmitted drug resistance on the natural history of HIV infection and response to first-line therapy. AIDS, 2006; 20,1:21–28.
7.
JainV, LieglerT, VittinghoffE, HartogensisW, BacchettiP, PooleLet al.Transmitted drug resistance in persons with acute/early HIV-1 in San Francisco, 2002–2009. PLoS ONE, 2010; 5,12:e15510.
8.
RahimS, FredrickLM, da SilvaBA, BernsteinB, KingMS. Geographic and temporal trends of transmitted HIV-1 drug resistance among antiretroviral-naïve subjects screening for two clinical trials in North America and Western Europe. HIV Clin Trials, 2009; 10,2:94–103.
9.
WheelerWH, ZiebellRA, ZabinaH, PieniazekD, PrejeanJ, BodnarURet al.Prevalence of transmitted drug resistance associated mutations, HIV-1 subtypes in new HIV-1 diagnoses, U.S.-2006. AIDS, 2010; 24,8:1203–1212.
10.
von WylV, YerlyS, BurgisserP, KlimkaitT, BattegayM, BernasconiEet al.Long-term trends of HIV type 1 drug resistance prevalence among antiretroviral treatment-experienced patients in Switzerland. Clin Infect Dis, 2009; 48,7:979–987.
11.
CostagliolaD, DescampsD, AssoumouL, Morand-JoubertL, MarcelinA, BrodardVet al.Prevalence of HIV-1 drug resistance in treated patients: A French nationwide study. J Acquir Immune Defic Syndr, 2007; 46,1:12–18.
12.
VercauterenJ, WensingAMJ, van de VijverDAMC, AlbertJ, BalottaC, HamoudaOet al.Transmission of drug-resistant HIV-1 is stabilizing in Europe. J Infect Dis, 2009; 200,10:1503–1508.
13.
BraccialeL, ColafigliM, ZazziM, CorsiP, MeravigliaP, MicheliVet al.Prevalence of transmitted HIV-1 drug resistance in HIV-1-infected patients in Italy: Evolution over 12 years and predictors. J Antimicrob Chemother, 2009; 64,3:607–615.
14.
SaxPE, IslamR, WalenskyRP, LosinaE, WeinsteinMC, GoldieSJet al.Should resistance testing be performed for treatment-naive HIV-infected patients? A cost-effectiveness analysis. Clin Infect Dis, 2005; 41,9:1316–1323.
15.
WeinsteinMC, GoldieSJ, LosinaE, CohenCJ, BaxterJD, ZhangHet al.Use of genotypic resistance testing to guide HIV therapy: Clinical impact and cost-effectiveness. Ann Intern Med, 2001; 134,6:440–450.
16.
Panel on Antiretroviral Guidelines for Adults and Adolescents: Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. May4, 2006; 1–1122011 Jan 18http://aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL05042006050.pdf
RiddlerSA, HaubrichR, DiRienzoAG, PeeplesL, PowderlyWG, KlingmanKLet al.Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med, 2008; 358,20:2095–2106.
19.
DaarES, TierneyC, FischlMA, SaxPE, MollanK, BudhathokiCet al.Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV type-1: A randomized trial. Ann Intern Med, 2011; 154,7:445–456.
20.
PulsRL, SrasuebkulP, PetoumenosK, BoeseckeC, DuncombeC, BellosoWHet al.Efavirenz versus boosted atazanavir or zidovudine and abacavir in antiretroviral treatment-naive, HIV-infected subjects: Week 48 data from the Altair Study. Clin Infect Dis, 2010; 51,7:855–864.
21.
KimberlyS, TiernneyC, DaarE, MollanK, BudhathokiC, SaxPet al.Association of Race/Ethnicity and Sex on Outcomes in ACTG Study A5202. [Abstract 536]Presented at the 18th Conference on Retroviruses and Opportunistic Infections, February 27–March 2, 2011, Boston.
KimD, WheelerW, ZiebellRet al.Prevalence of transmitted antiretroviral drug resistance among newly-diagnosed HIV-1-infected persons, US, 2007. [Abstract 580]Presented at the 17th Conference on Retroviruses and Opportunistic Infections, February 16–19, 2010, San Francisco.
24.
MugaveroMJ, MayM, HarrisR, SaagMS, CostagliolaD, EggerMet al.Does short-term virologic failure translate to clinical events in antiretroviral-naïve patients initiating antiretroviral therapy in clinical practice?AIDS, 2008; 22,18:2481–2492.
